Fly News Breaks for January 2, 2020
Jan 2, 2020 | 07:08 EDT
Piper Jaffray analyst Edward Tenthoff noted that Gilead raised list prices by 4.8% on the company's top five selling HIV antiviral drugs, which he notes is in-line with last year's price increases. Tenthoff, who said the HIV drug price hikes "appear responsible" given that they are in-line with the median 5% price increase taken by large pharma for 2020 and "well below" the high single-digit hikes observed with some other companies, keeps a Neutral rating on Gilead shares.
News For GILD From the Last 2 Days
There are no results for your query GILD